Original Literature | Model OverView |
---|---|
Publication
Title
Regulation of cytokine signaling by SOCS family molecules.
Affiliation
Department of Molecular Medicine, Osaka University Graduate School of Medicine,2-2, Yamadaoka, Suita City, Osaka, Japan.
Abstract
Cytokine signaling is dependent on the activation of intracellular molecules,including JAKs (Janus family kinases) and STATs (signal transducers andactivators of transcription). Since the discovery of the SOCS (suppressor ofcytokine signaling) family molecules in 1997, extensive investigation of thesemolecules has given important insights into the as yet unclarified regulatorymechanisms of cytokine signaling. Recent gene targeting analyses of SOCSmolecules have revealed that they do indeed have essential roles in vivo (morespecific than those expected from overexpression studies in vitro) in thenegative regulation of various cytokines. Moreover, consistent with thepathological actions of cytokines in human diseases, recent lines of evidencealso indicate that SOCS molecules are implicated in autoimmunity, allergy andcancers.
PMID
14644140
|
Entity
STAT5
--
MO000016876
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1798
10
infinite
0
TRANSPATH | MO000016876 |
--
SOCS-1
--
MO000017004
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1906
10
infinite
0
InterPro | IPR001496 |
TRANSPATH | MO000017004 |
--
CIS
--
MO000017116
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2003
10
infinite
0
InterPro | IPR001496 |
TRANSPATH | MO000017116 |
--
SOCS-2
--
MO000017120
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2004
10
infinite
0
InterPro | IPR001496 |
TRANSPATH | MO000017120 |
--
SOCS-3
--
MO000017121
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2005
10
infinite
0
InterPro | IPR001496 |
TRANSPATH | MO000017121 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
IL-2:IL-2R
--
e11
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m11
0
infinite
0
--
IL-3:IL-3R
--
e12
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m12
0
infinite
0
--
LIgand:EpoR:CIS
--
e13
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m13
0
infinite
0
--
Ligand:Prolactin
--
e14
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m14
0
infinite
0
--
csml-variable:Double
m15
0
infinite
0
--
JAK
--
e16
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m16
0
infinite
0
--
SOCS-1:JAK
--
e17
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m17
0
infinite
0
--
SOCS-1:Vav
--
e18
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m18
0
infinite
0
--
SOCS-1:IRS-1
--
e19
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
SOCS-1:iRAK
--
e20
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m20
0
infinite
0
--
GH:GHR:SOCS-2
--
e21
cso30:c:Complex
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m21
0
infinite
0
--
GH:GHR
--
e22
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m22
0
infinite
0
--
IGF-1:IGF-1R
--
e24
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m24
0
infinite
0
--
SOCS-3{p}
--
e25
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m25
0
infinite
0
--
LIgand:EpoR{ub}:CIS
--
e27
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m28
0
infinite
0
--
Insulin:Insulin receptor
--
e28
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m29
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
protein kinase B
--
e31
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m32
0
infinite
0
--
protein kinase B {active}
--
e32
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m33
0
infinite
0
--
SOCS6:IRS-4
--
e34
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m35
0
infinite
0
--
Ligand:gp130
--
e35
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m36
0
infinite
0
--
IL-2:IL-2R:CIS
--
e36
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m37
0
infinite
0
--
IFN responsive genes
--
e38
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m39
0
infinite
0
--
Ligand:Prolactin:CIS
--
e39
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m40
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
Ligand:EpoR:SOCS-3
--
e40
cso30:c:Complex
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m42
0
infinite
0
--
IL-3:IL-3R:CIS
--
e41
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m43
0
infinite
0
--
Ligand:gp130:SOCS-3
--
e42
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m44
0
infinite
0
--
IGF-1:IGF-1R:SOCS-2
--
e43
cso30:c:Complex
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m45
0
infinite
0
--
Insulin:Insulin receptor:SOCS6
--
e44
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m46
0
infinite
0
--
Ligand
--
e45
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m47
0
infinite
0
--
SOCS-1:Vav{ub}
--
e46
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m48
0
infinite
0
--
degradants
--
e47
cso30:c:EntityBiological
cso30:i:CC_Cytosol
--
csml-variable:Double
m49
0
infinite
0
--
SOCS-1:IRS-1{ub}
--
e48
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m63
0
infinite
0
--
SOCS-1:JAK{ub}
--
e49
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m64
0
infinite
0
--
Ligand:EpoR
--
e5
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
GH:GHR:CIS
--
e6
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
STAT5{active}
--
e63
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m65
10
infinite
0
TRANSPATH | MO000016876 |
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c3 : 1
stoichiometry:c80 : 1
m2003*m5*0.1
nodelay
--
0
PMID: 14644140,9129017,10585430 The SH2 domain of the CIS associates with STAT5-binding sites of various types of receptor, including growth hormone (GH) receptors and EPO receptors
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c26 : 1
stoichiometry:c25 : 1
stoichiometry:c27 : 1
m41*m1906*0.1
nodelay
--
0
PMID: 14644140 Based on the results of in vitro studies using cell lines forcedly expressing SOCS-1, it has been confirmed that SOCS-1 inhibits various types of signal transduction through its binding to JAK and possibly other signaling molecules, such as Vav, IRS-1 sand IL-1 receptor-associated kinase (IRAK)
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c28 : 1
stoichiometry:c29 : 1
stoichiometry:c30 : 1
m1906*m135*0.1
nodelay
--
0
PMID: 14644140 Based on the results of in vitro studies using cell lines forcedly expressing SOCS-1, it has been confirmed that SOCS-1 inhibits various types of signal transduction through its binding to JAK and possibly other signaling molecules, such as Vav, IRS-1 sand IL-1 receptor-associated kinase (IRAK)
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c32 : 1
stoichiometry:c33 : 1
m1906*m184*0.1
nodelay
--
0
PMID: 14644140 Based on the results of in vitro studies using cell lines forcedly expressing SOCS-1, it has been confirmed that SOCS-1 inhibits various types of signal transduction through its binding to JAK and possibly other signaling molecules, such as Vav, IRS-1 sand IL-1 receptor-associated kinase (IRAK)
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c35 : 1
stoichiometry:c89 : 1
stoichiometry:c34 : 1
m2004*m22*0.1
nodelay
--
0
PMID: 14644140,12208853,10403376 SOCS-2 is known to bind to the SHP2-binding site of activated GH receptors and to inhibit the activation of STAT5b induced by GH
p14
p14
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c37 : 1
stoichiometry:c38 : 1
stoichiometry:c39 : 1
m2633*m2174*0.1
nodelay
--
0
PMID: 14644140,12208853,10403376 SOCS-2 is known to bind to the SHP2-binding site of activated GH receptors and to inhibit the activation of STAT5b induced by GH
p15
p15
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c40 : 1
stoichiometry:c41 : 1
stoichiometry:c42 : 1
m1371*m22*0.1
nodelay
--
0
PMID: 14644140,12208853,10403376 SOCS-2 is known to bind to the SHP2-binding site of activated GH receptors and to inhibit the activation of STAT5b induced by GH
p16
p16
cso30:i:ME_Translation
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c45 : 1
stoichiometry:c46 : 1
stoichiometry:c44 : 1
m96897*m22*0.1
nodelay
--
0
Growth promotion by GH is dependent on the induction of insulin-like growth factor-1 (IGF-1) by GH, whereas SOCS-2-deficient mice do not exhibit an increase in serum IGF-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c47 : 1
stoichiometry:c49 : 1
stoichiometry:c43 : 1
m2004*m24*0.1
nodelay
--
0
PMID: 14644140,12208853,9727029 SOCS-2 binds not only to GH receptors but also to IGF-1 receptors
p18
p18
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c50 : 1
stoichiometry:c51 : 1
stoichiometry:c52 : 1
m1954*m2005*0.1
nodelay
--
0
PMID: 14644140,11331873 In addition, in vitro data have suggested that SOCS-3 undergoes tyrosine-phosphorylation on stimulation with IL-2 and appears to accelerate the activation of ErK (extracellular-signal-regulated kinase) by acting as an adaptor molecule
p19
p19
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c53 : 1
stoichiometry:c55 : 1
stoichiometry:c54 : 1
m26*m25*0.1
nodelay
--
0
PMID: 14644140,11331873 In addition, in vitro data have suggested that SOCS-3 undergoes tyrosine-phosphorylation on stimulation with IL-2 and appears to accelerate the activation of ErK (extracellular-signal-regulated kinase) by acting as an adaptor molecule
p1
p2
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c5 : 1
stoichiometry:c6 : 1
stoichiometry:c88 : 1
m2003*m2174*m22*0.1
nodelay
--
0
PMID: 14644140,9129017,10585430 The SH2 domain of the CIS associates with STAT5-binding sites of various types of receptor, including growth hormone (GH) receptors and EPO receptors PMID: 14644140,7796808 Initial in vitro studies reported CIS as an inhibitor of the signal transduction of EPO, interleukin-2 (IL-2), IL-3, GH and prolactin, by masking the STAT5-binding sites of receptors and inhibiting the activation of STAT5.
p20
p20
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c58 : 1
stoichiometry:c57 : 1
m94812*m871*0.1
nodelay
--
0
PMID: 14644140,9889194 SOCS-5 is induced in M1 cell lines in response to stimulation with IL-6 and marginally inhibits IL-6 signaling
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c59 : 1
stoichiometry:c48 : 1
stoichiometry:c61 : 1
m37538*m29*0.1
nodelay
--
0
PMID: 14644140,11342531 SOCS-6 binds to insulin receptors and inhibits the activation of Erk1/2, protein kinase B and IRS-1
p22
p22
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c78 : 1
stoichiometry:c63 : 1
m549*0.1
nodelay
--
0
PMID: 14644140,11342531 SOCS-6 binds to insulin receptors and inhibits the activation of Erk1/2, protein kinase B and IRS-1
p22
p23
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c66 : 1
stoichiometry:c64 : 1
stoichiometry:c67 : 1
m554*0.1
nodelay
--
0
PMID: 14644140,11342531 SOCS-6 binds to insulin receptors and inhibits the activation of Erk1/2, protein kinase B and IRS-1
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c69 : 1
stoichiometry:c65 : 1
stoichiometry:c70 : 1
m32*0.1
nodelay
--
0
PMID: 14644140,11342531 SOCS-6 binds to insulin receptors and inhibits the activation of Erk1/2, protein kinase B and IRS-1
p22
p25
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c72 : 1
stoichiometry:c68 : 1
stoichiometry:c73 : 1
m135*0.1
nodelay
--
0
PMID: 14644140,11342531 SOCS-6 binds to insulin receptors and inhibits the activation of Erk1/2, protein kinase B and IRS-1
p26
p26
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c74 : 1
stoichiometry:c75 : 1
stoichiometry:c76 : 1
m37538*m1793*0.1
nodelay
--
0
PMID: 14644140,12052866 Interestingly, a recent study has reported that SOCS-6 binds to IRS-4, a molecule with an important role in insulin signaling, and that SOCS-6-deficient mice exhibit mild growth retardation
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c77 : 1
stoichiometry:c79 : 1
stoichiometry:c36 : 1
m2005*0.1
nodelay
--
0
PMID: 14644140,12626585 It is noteworthy that this notion is in line with the recent finding that SOCS-3 associates with gp130 but not with the IL-10 receptor (IL-10R), and endogenous SOCS-3 induced by cytokines inhibits IL-6 signaling but not IL-10 signaling in human macrophages PMID: 14644140 SOCS-3 inhibits the function of JAK by binding to the Src homology phosphatase-2 (SHP-2)-binding domain of gp130 and the EPORs
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c81 : 1
stoichiometry:c2 : 1
stoichiometry:c82 : 1
m2005*m5*0.1
nodelay
--
0
PMID: 14644140 SOCS-3 inhibits the function of JAK by binding to the Src homology phosphatase-2 (SHP-2)-binding domain of gp130 and the EPORs
p29
p29
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c83 : 1
stoichiometry:c84 : 1
stoichiometry:c85 : 1
m871*m1357*0.1
nodelay
--
0
PMID: 14644140,12754506 Other groups showed that IL-6 strongly activates STAT1 and induces the expression of IFN-responsive genes in SOCS-3 deficient macrophages, implying that IL-6 could mimic the action of IFNs
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c9 : 1
stoichiometry:c8 : 1
m2003*m11*0.1
nodelay
--
0
PMID: 14644140,7796808 Initial in vitro studies reported CIS as an inhibitor of the signal transduction of EPO, interleukin-2 (IL-2), IL-3, GH and prolactin, by masking the STAT5-binding sites of receptors and inhibiting the activation of STAT5.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c86 : 1
stoichiometry:c87 : 1
m38*0.1
nodelay
--
0
PMID: 14644140,12754506 Other groups showed that IL-6 strongly activates STAT1 and induces the expression of IFN-responsive genes in SOCS-3 deficient macrophages, implying that IL-6 could mimic the action of IFNs
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c60 : 1
stoichiometry:c71 : 1
m13*0.1
nodelay
--
0
PMID: 14644140,9774439 CIS is also involved in the ubiquitination and degradation of EPO receptors
p32
p32
cso30:i:ME_UnknownDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c90 : 1
stoichiometry:c91 : 1
stoichiometry:c92 : 1
m28*0.1
nodelay
--
0
PMID: 14644140,9774439 CIS is also involved in the ubiquitination and degradation of EPO receptors
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c98 : 1
stoichiometry:c99 : 1
m19*0.1
nodelay
--
0
PMID: 14644140,10747851,12228220,11971965 Indeed, SOCS-1 accelerates ubiquitination and degradation of Vav, insulin receptor substrate-1 (IRS-1) and JAKs that can associate with SOCS-1
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c93 : 1
stoichiometry:c94 : 1
m18*0.1
nodelay
--
0
PMID: 14644140,10747851,12228220,11971965 Indeed, SOCS-1 accelerates ubiquitination and degradation of Vav, insulin receptor substrate-1 (IRS-1) and JAKs that can associate with SOCS-1
p35
p35
cso30:i:ME_UnknownDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c95 : 1
stoichiometry:c96 : 1
stoichiometry:c97 : 1
m48*0.1
nodelay
--
0
PMID: 14644140,10747851,12228220,11971965 Indeed, SOCS-1 accelerates ubiquitination and degradation of Vav, insulin receptor substrate-1 (IRS-1) and JAKs that can associate with SOCS-1
p36
p36
cso30:i:ME_UnknownDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c100 : 1
stoichiometry:c101 : 1
stoichiometry:c102 : 1
m63*0.1
nodelay
--
0
PMID: 14644140,10747851,12228220,11971965 Indeed, SOCS-1 accelerates ubiquitination and degradation of Vav, insulin receptor substrate-1 (IRS-1) and JAKs that can associate with SOCS-1
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c103 : 1
stoichiometry:c104 : 1
m17*0.1
nodelay
--
0
PMID: 14644140,10747851,12228220,11971965 Indeed, SOCS-1 accelerates ubiquitination and degradation of Vav, insulin receptor substrate-1 (IRS-1) and JAKs that can associate with SOCS-1
p35
p38
cso30:i:ME_UnknownDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c105 : 1
stoichiometry:c106 : 1
stoichiometry:c107 : 1
m64*0.1
nodelay
--
0
PMID: 14644140,10747851,12228220,11971965 Indeed, SOCS-1 accelerates ubiquitination and degradation of Vav, insulin receptor substrate-1 (IRS-1) and JAKs that can associate with SOCS-1
p39
p39
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c108 : 1
stoichiometry:c110 : 1
stoichiometry:c109 : 1
m1798*0.1
nodelay
--
0
PMID: 14644140,7796808 Initial in vitro studies reported CIS as an inhibitor of the signal transduction of EPO, interleukin-2 (IL-2), IL-3, GH and prolactin, by masking the STAT5-binding sites of receptors and inhibiting the activation of STAT5.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c12 : 1
stoichiometry:c11 : 1
m2003*0.1
nodelay
--
0
PMID: 14644140,7796808 Initial in vitro studies reported CIS as an inhibitor of the signal transduction of EPO, interleukin-2 (IL-2), IL-3, GH and prolactin, by masking the STAT5-binding sites of receptors and inhibiting the activation of STAT5.
p39
p40
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c111 : 1
stoichiometry:c112 : 1
stoichiometry:c113 : 1
m1798*0.1
nodelay
--
0
PMID: 14644140,7796808 Initial in vitro studies reported CIS as an inhibitor of the signal transduction of EPO, interleukin-2 (IL-2), IL-3, GH and prolactin, by masking the STAT5-binding sites of receptors and inhibiting the activation of STAT5.
p39
p41
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c114 : 1
stoichiometry:c115 : 1
stoichiometry:c116 : 1
m1798*0.1
nodelay
--
0
PMID: 14644140,7796808 Initial in vitro studies reported CIS as an inhibitor of the signal transduction of EPO, interleukin-2 (IL-2), IL-3, GH and prolactin, by masking the STAT5-binding sites of receptors and inhibiting the activation of STAT5.
p39
p42
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c117 : 1
stoichiometry:c118 : 1
stoichiometry:c119 : 1
m1798*0.1
nodelay
--
0
PMID: 14644140,7796808 Initial in vitro studies reported CIS as an inhibitor of the signal transduction of EPO, interleukin-2 (IL-2), IL-3, GH and prolactin, by masking the STAT5-binding sites of receptors and inhibiting the activation of STAT5.
p39
p43
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c120 : 1
stoichiometry:c122 : 1
stoichiometry:c121 : 1
m1798*0.1
nodelay
--
0
PMID: 14644140,7796808 Initial in vitro studies reported CIS as an inhibitor of the signal transduction of EPO, interleukin-2 (IL-2), IL-3, GH and prolactin, by masking the STAT5-binding sites of receptors and inhibiting the activation of STAT5.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c15 : 1
stoichiometry:c14 : 1
m2003*m14*0.1
nodelay
--
0
PMID: 14644140,7796808 Initial in vitro studies reported CIS as an inhibitor of the signal transduction of EPO, interleukin-2 (IL-2), IL-3, GH and prolactin, by masking the STAT5-binding sites of receptors and inhibiting the activation of STAT5.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c17 : 1
m908*0.1
nodelay
--
0
PMID: 14644140,10453004,11390452,12433365,12433373,11208867 However, SOCS-1 expression is now known to be induced by insulin, lipopolysaccharide (LPS), CpG DNA and other molecules that do not use STATs in signal transduction
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c18 : 1
stoichiometry:c19 : 1
m155666*0.1
nodelay
--
0
PMID: 14644140,10453004,11390452,12433365,12433373,11208867 However, SOCS-1 expression is now known to be induced by insulin, lipopolysaccharide (LPS), CpG DNA and other molecules that do not use STATs in signal transduction
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c20 : 1
stoichiometry:c21 : 1
m15*0.1
nodelay
--
0
PMID: 14644140,10453004,11390452,12433365,12433373,11208867 However, SOCS-1 expression is now known to be induced by insulin, lipopolysaccharide (LPS), CpG DNA and other molecules that do not use STATs in signal transduction
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c22 : 1
stoichiometry:c23 : 1
stoichiometry:c24 : 1
m1906*m16*0.1
nodelay
--
0
PMID: 14644140 Based on the results of in vitro studies using cell lines forcedly expressing SOCS-1, it has been confirmed that SOCS-1 inhibits various types of signal transduction through its binding to JAK and possibly other signaling molecules, such as Vav, IRS-1 sand IL-1 receptor-associated kinase (IRAK) PMID: 14644140 Currently, SOCS-1 is thought to inhibit the catalytic activity of JAKs by directly binding to the JAK activation loop with both its SH2 and KIR domains and preventing the access of JAK substrates with its KIR domain.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--